HBVNCT07007286
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
An observational study of HBV and HCC, run by Peking University First Hospital at 555 sites in China.
Trial summary
This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. Read more about this study
- Who is it for?
- Ages 30 years and older
- What is being tested?
- ETV,TDF,TAF,TMF combination with PEG IFNα-2b and ETV,TDF,TAF or TMF
- How many people
- 1,500 participants
- Where
- 555 sitesChina
- Study dates
- Jun 2025to Dec 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who meet the inclusion criteria but do not meet the exclusion criteria were screened from multiple centers nationwide.
Who may be able to join
- (1) Chronic hepatitis B (CHB) patients with HBsAg positivity for over 6 months; (2) Family history of HBV-related hepatocellular carcinoma (HCC) (first- or second-degree relatives with HBV-related HCC); (3) Age ≥ 30 years, regardless of gender; (4) Based on real-world clinical practice, patients receiving nucleos(t)ide analogue (NA) therapy, such as Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide Fumarate (TAF), or Tenofovir Amibufenamide (TMF), or those receiving combination therapy with nucleos(t)ide analogues and PEG IFNα-2b; (5) Negative pregnancy test within 24 hours before the first dose (for women of childbearing potential); (6) Voluntary participation, with the ability to understand and sign the informed consent form.
Who cannot join
- (1) Patients diagnosed with hepatocellular carcinoma (HCC) or malignancies in other organ systems prior to treatment; (2) Patients with contraindications to Peg IFN α-2b (refer to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition) for details); (3) Patients in the immune-tolerant phase of HBV infection; (4) Patients scheduled for or with a history of organ transplantation; (5) Patients with hypersensitivity to interferon or any contraindication listed in the drug's prescribing information; (6) Other conditions deemed unsuitable for enrollment by the investigator.
Trial locations and contacts
555 sites in 1 country. Contact the study team or a site near you to ask about taking part.
300 sites in 1 country
China300 sites
Anfu County People's Hospital
Anfu
Zhiyun Peng
Ankang Central Hospital
Ankang
Xuemei Li
Ankang Hospital of Traditional Chinese Medicine
Ankang
Xiang Cui
Anning Hospital of Traditional Chinese Medicine
Anning
Qiuhong Liu
Anqing First People's Hospital
Anqing
Feng He
Anqing Municipal Hospital
Anqing
Zhenjun Liu
Anshan Infectious Disease Hospital
Anshan
Yang Xu
Anyue County People's Hospital
Anyue
Guanglin Pu
Affiliated Hospital of Youjiang Medical University for Nationalities
Baise City
Baoding First Central Hospital
Baoding
Guangzhou Gao
Baoding People's Hospital
Baoding
Musong Li
Baotou Central Hospital
Baotou
Jing Wang
China National Medicines (CNM) Northern Hospital
Baotou
Yongqing Ren
The Third Staff Hospital of Baotou Steel Group
Baotou
Kun Yan
Beihai People's Hospital
Beihai
Feng Long
Beijing Daxing District People's Hospital
Beijing
Xia Liu
Beijing Ditan Hospital, Capital Medical University
Beijing
Yao Xie
Beijing Ditan Hospital
Beijing
Yao Xie
Beijing Fangshan District First Hospital
Beijing
Xiuying Xie
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Beijing
Li Li
Beijing Huaxin Hospital
Beijing
Qinbing Zeng
Beijing Liangxiang Hospital, Fangshan District
Beijing
Juan Zhou
Beijing Tsinghua Changgung Hospital
Beijing
Ming Yang
Beijing You'an Hospital, Capital Medical University
Beijing
Sujun Zheng
Beijing You'an Hospital
Beijing
Sujun Zheng
Dongfang Hospital, Beijing University of Chinese Medicine
Beijing
Dongzhimen Hospital, Beijing University of Chinese Medicine
Beijing
Hongbo Du
Peking University People's Hospital
Beijing
Bo Feng
Peking University Third Hospital
Beijing
Ming Lu
Shunyi Hospital of Traditional Chinese Medicine, Beijing
Beijing
Li Li
The Fifth Medical Center of PLA General Hospital
Beijing
Junliang Fu
Wangfu Hospital of Integrated Traditional Chinese and Western Medicine
Beijing
Lin Zhu
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Beijing
Yinqiang Zhang
Xuanwu Hospital, Capital Medical University
Beijing
Geng Tian
Bengbu Fifth People's Hospital
Bengbu
Zheng Liu
Guzhen County Hospital of Traditional Chinese Medicine
Bengbu
Guzhen County People's Hospital
Bengbu
Tong Wang
The First Affiliated Hospital of Bengbu Medical University
Bengbu
Chuanmiao Liu
Benxi Sixth People's Hospital
Benxi
Hua Jin
Beihai Tuberculosis Prevention and Treatment Hospital
Bihua
Bihua Gao
Binzhou Central Hospital
Binzhou
Ying Jiang
Binzhou People's Hospital
Binzhou
Kai Zuo
Bozhou Hospital of Traditional Chinese Medicine
Bozhou
Daping Du
Bozhou People's Hospital
Bozhou
Lan Ma
Lixin County People's Hospital
Bozhou
Jing Xu
Mengcheng First People's Hospital
Bozhou
Pengfei Xie
Cangzhou Third Hospital
Cangzhou
Aihua Gao
The First Hospital of Jilin University
Changchun
Yanhang Gao
Changji Branch of the First Affiliated Hospital of Xinjiang Medical University
Changji
Min Chen
Changji Hui Autonomous Prefecture People's Hospital
Changji
Jiangtao Liu
Changle County People's Hospital
Changle, Shandong
Changxing County People's Hospital
Changxing
Xiaoxue Xia
Changzhi People's Hospital
Changzhi
Hong Wu
Heping Hospital Affiliated to Changzhi Medical College
Changzhi
Suling Chen
Changzhou Third People's Hospital
Changzhou
Yuan Xue
Yizheng People's Hospital
Changzhou
Hongxia Ma
Chaoyang Fourth Hospital
Chaoyang
Jinghai Du
Kazuo County Central Hospital
Chaoyang
Hongguang Fan
Chengdu Fifth People's Hospital
Chengdu
Xiaomei Xu
Chengdu Public Health Clinical Medical Center
Chengdu
Li Zhu
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu
Xingxiang Yang
West China Hospital, Sichuan University
Chengdu
Xuezhong Lei
Chifeng Baoshan Hospital
Chifeng
Yuqin Wan
Chifeng Songshan Traditional Chinese Medicine & Mongolian Medicine Hospital
Chifeng
Changling Dong
Chifeng Tumor Hospital
Chifeng
Lichun Yang
Chizhou People's Hospital
Chizhou
Xiaoling Liu
Mingguang People's Hospital
Chuzhou
Zhen Fang
Dali Bai Autonomous Prefecture People's Hospital
Dali
Huiyong Su
The First Affiliated Hospital of Dalian Medical University
Dalian
Ying Zhu
Dandong Sixth People's Hospital
Dandong
Hui Liu
Daqing Second Hospital
Daqing
Zhen Lü
China National Medicines & Health Products Datong Coal Mine Group General Hospital
Datong
Jingning Yang
Datong Fourth People's Hospital
Datong
Riwang Hu
Donggang Central Hospital
Donggang
Ming Jiang
Dongguan Eastern Central Hospital
Dongguan
Dongben Gao
Dongguan Ninth People's Hospital
Dongguan
Lihua Zhang
Dongtai People's Hospital
Dongtai
Xiaoqiang Zhong
Dongying Hospital of Traditional Chinese Medicine
Dongying
Xiangmeng Cao
Dongying People's Hospital
Dongying
Pengyan Li
Shengli Oilfield Central Hospital
Dongying
Xue Feng
Jianshi County People's Hospital
Enshi
Zaixing Huang
Lichuan Traditional Chinese Medicine Hospital for Ethnic Minorities
Enshi
Xiaoyu Zhao
Ezhou Central Hospital
Ezhou
Wenjin Sun
Fengcheng People's Hospital
Fengcheng
Feibing Luo
Fenyang Hospital
Fenyang
Yaosheng Quan
Foshan Hospital of Traditional Chinese Medicine
Foshan
Xiaojun Ma
Sanshui Hospital of Zhujiang Hospital, Southern Medical University
Foshan
Yinhui Liu
Shunde Hospital Affiliated to Jinan University
Foshan
Bin Liu
The Eighth Affiliated Hospital of Southern Medical University
Foshan
Hong Li
The Fourth People's Hospital of Foshan
Foshan
Weijin Gong
Fuxin Infectious Disease Hospital
Fuxin
Xinyu Li
Fuyang Fifth People's Hospital
Fuyang
Xinggang Fan
Fuyang Hospital Affiliated to Anhui Medical University
Fuyang
Lizhou Zhang
Fuyang People's Hospital
Fuyang
Baogui Wang
Fuyang Second People's Hospital
Fuyang
Ming Li
Linquan County People's Hospital
Fuyang
Changfeng Wu
Taihe County Hospital of Traditional Chinese Medicine
Fuyang
Lianye Zhang
Jinxi County People's Hospital
Fuzhou
Jianping Jiang
Lichuan County People's Hospital
Fuzhou
Hongqi Yan
Linchuan District First People's Hospital
Fuzhou
Yansun Wu
Nanfeng County People's Hospital
Fuzhou
Xin Zeng
The First Affiliated Hospital of Fujian Medical University
Fuzhou
Yueyong Zhu
Dingnan County First People's Hospital
Ganzhou
Ping Chen
Ganzhou Fifth People's Hospital
Ganzhou
Yingmin Luo
Ganzhou People's Hospital
Ganzhou
Jie Liu
Yudu County People's Hospital
Ganzhou
Yonghong Deng
Gaomi People's Hospital
Gaomi
Jinxin Sun
Guangzhou Eighth People's Hospital, Guangzhou Medical University
Guangzhou
Keli Yang
Guangzhou First People's Hospital
Guangzhou
Qi Zhan
Guangzhou Medical University Affiliated Panyu Central Hospital
Guangzhou
Yumei Chen
Huadu District People's Hospital, Guangzhou
Guangzhou
Peiyan Xu
Nansha District People's Hospital, Guangzhou
Guangzhou
Yangli Zhang
Panyu District Maternal and Child Health Hospital, Guangzhou
Guangzhou
Yankun He
Shijing People's Hospital, Baiyun District, Guangzhou
Guangzhou
Liujiao Fang
The Fourth Affiliated Hospital of Guangzhou Medical University
Guangzhou
Qiwen Wu
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou
Xingfei Pan
The Third Affiliated Hospital of Southern Medical University
Guangzhou
Chuangguo Yang
Guilin Hospital of Traditional Chinese Medicine
Guilin
Ming Jiang
The Third People's Hospital of Guilin
Guilin
Yongchao Xian
Xing'an County People's Hospital
Guilin
Huanwen Chen
Hainan Provincial People's Hospital
Haikou
Li Shi
Hailin People's Hospital
Hailin
Hongwei Wang
Hami Central Hospital
Hami
Chuanjian Shi
Xinjiang Production and Construction Corps 13th Division Hongxing Hospital
Hami
Jin Yang
Handan Central Hospital
Handan
Huanhuan Song
Handan First Hospital
Handan
Hexian Cui
Handan Fourth Hospital
Handan
Zhiguo Sun
Handan Infectious Disease Hospital
Handan
Zhenhai Ning
Linzhang County People's Hospital
Handan
Guocheng Wang
Wei County People's Hospital
Handan
Chao Gao
Yongnian District First People's Hospital
Handan
Xuelian Li
Hangzhou Xixi Hospital
Hangzhou
Wenjun Ma
Lin'an District First People's Hospital
Hangzhou
Yuefei Shen
Linping District Hospital of Traditional Chinese Medicine
Hangzhou
Yuejiao Cao
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou
Yi Zheng
Chenggu County People's Hospital
Hanzhong
Jin Li
Hanbin District First Hospital
Hanzhong
Bengong Ye
Hanzhong Second People's Hospital
Hanzhong
Weijia Zhao
Yang County People's Hospital
Hanzhong
Hong Chang
Acheng District People's Hospital of Harbin
Harbin
Haisheng Song
Harbin First Hospital
Harbin
Linlin Na
Harbin Sixth Hospital
Harbin
Lin Zhang
Heilongjiang Provincial Hospital
Harbin
Xiaoli Hu
The First Affiliated Hospital of Harbin Medical University
Harbin
Guolin Chen
The Fourth Affiliated Hospital of Harbin Medical University
Harbin
Lihua Zhong
The Second Affiliated Hospital of Harbin Medical University
Harbin
Ming Liang
Gu'an County Hospital of Traditional Chinese Medicine
Hebei
Yubo Zhang
Anhui Provincial Hospital
Hefei
Hongliang He
Hefei First People's Hospital Binhu Branch
Hefei
Limin Liang
Hefei First People's Hospital
Hefei
Jishun Zheng
Hefei Second People's Hospital
Hefei
Jiling Wang
Hefei Third People's Hospital
Hefei
Chunhua Fang
The First Affiliated Hospital of Anhui Medical University
Hefei
Liyu Zhu
Hegang Infectious Disease Hospital
Hegang
Chunping Liu
Hegang Mining General Hospital
Hegang
Tao Wang
Beian First People's Hospital
Heihe
Yahui Ma
Heihe First People's Hospital
Heihe
Xiujuan Chen
Qitaihe Infectious Disease Hospital
Heilongjiang, Heilongjiang
Bohui Yuan
Hengshui Third People's Hospital
Hengshui
Suoxiang Zhang
Hotan Prefecture Specialized Hospital for Infectious Diseases
Hetian
Wubulai Aishan Maimaitijiang
Heze Municipal Hospital
Heze
Fangqi Ge
Hezhou People's Hospital
Hezhou
Fan Li
Affiliated Hospital of Inner Mongolia Medical University
Hohhot
Zhen Ma
Hohhot Second Hospital
Hohhot
Jianming Li
Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine
Hohhot
Ruixiu Xiao
The 969th Hospital of the Joint Logistics Support Force
Hohhot
Cai Chen
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot
Xiaoying Xu
Hongze District People's Hospital
Huai'an
Jian Tan
Huai'an Fifth People's Hospital
Huai'an
Xuezhen Zhai
Huai'an Fourth People's Hospital
Huai'an
Chun Lü
Huai'an No. 82 Hospital
Huai'an
Zhaorong Jiang
Huainan First People's Hospital
Huainan
Yanzhong Wang
Huangshan Huangshan People's Hospital
Huangshan City
Xianjin Xie
Huangshan People's Hospital
Huangshan City
Yongjin Yang
Qimen County People's Hospital
Huangshan City
Xiang Zhang
Xiuning County People's Hospital
Huangshan City
Wei Zhang
Daye People's Hospital
Huangshi
Wen Chen
Huangshi Central Hospital
Huangshi
Zhiyong Zhang
Huangshi Hospital of Traditional Chinese Medicine
Huangshi
Zhilin Shao
Yangxin County People's Hospital
Huangshi
Xunhao Wang
Huazhong University of Science and Technology
Hubei
Zhengang Zhang
Huozhou Coal & Electricity Group General Hospital Co., Ltd.
Huozhou, Shanxi
Huozhou People's Hospital, Huozhou Medical Group
Huozhou, Shanxi
Wenfei Zhang
Huozhou People's Hospital
Huozhou, Shanxi
Wenfei Zhang
Ji'an Central People's Hospital
Ji’an
Haibin Yin
Jiamusi Infectious Disease Hospital
Jiamusi
Mingyou Li
Jiangmen Central Hospital
Jiangmen
Gang He
Xinhui People's Hospital
Jiangmen
Qingxia Zhou
Jianping County Hospital
Jianping
Honghua Kang
Tongji University Affiliated Oriental Hospital Jiaozhou
Jiaozhou
Huimin Li
Fenxi Mining Group Employees General Hospital
Jiexiu, Shanxi
Shuguang Hu
Jiexiu Medical Group People's Hospital
Jiexiu, Shanxi
Xiaobin Luo
Affiliated Hospital of Beihua University
Jilin City
Dalin Hao
Jilin City Infectious Disease Hospital
Jilin City
Yujie Wang
Jilin Provincial Hepatobiliary Hospital
Jilin City
Hui Chen
Qingdao Jimo District People's Hospital
Jimo
Jihong Zhang
Jinan People's Hospital
Jinan
Daojie Yan
Jiyang District Hospital of Traditional Chinese Medicine
Jinan
Jian Yao
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan
Wanhua Ren
Shandong Provincial Public Health Clinical Center
Jinan
Xiaoying Li
The First Affiliated Hospital of Shandong First Medical University
Jinan
Yong An
The Second Hospital of Shandong University
Jinan
Tao Li
Gaoping People's Hospital
Jincheng
Dongdong Cui
Jincheng People's Hospital
Jincheng
Yunlei Liang
Jincheng Third People's Hospital
Jincheng
Junmei Han
Zezhou County People's Hospital
Jincheng
Junjun Bi
Gong'an County People's Hospital
Jingzhou
Shijin Tian
Jingzhou Central Hospital
Jingzhou
Zheng Yang
The First People's Hospital of Jingzhou, Hubei
Jingzhou
Liya Zhu
Jinhua Municipal Central Hospital
Jinhua
Haijun Chen
Jining Public Health Medical Center
Jining
Chunsheng Hou
Jinxiang County People's Hospital
Jining
Jinxian County People's Hospital
Jinxian
Sangen Chen
Jinzhong First People's Hospital
Jinzhong
Liqing An
Shanxi Coking Coal Fenxi Mining Group Employees General Hospital
Jinzhong
Shuguang Hu
Jinzhou Central Hospital
Jinzhou
Yuanyuan Wang
Jinzhou Infectious Disease Hospital
Jinzhou
Yanhui Sun
Jiujiang Hospital of Traditional Chinese Medicine
Jiujiang
Yulin Chen
Jiujiang Third People's Hospital
Jiujiang
Zheng Wo
Jixi Infectious Disease Hospital
Jixi
Zhenjun Li
Juxian People's Hospital
Junxian, Shandong
Shanzhu Yu
Karamay Central Hospital
Karamay
Xin Da
Yunnan Provincial People's Hospital
Kunming
Jiawei Geng
Laixi People's Hospital
Laixi
Bochen Wang
Laizhou People's Hospital
Laizhou
Ruifen Chi
Lanzhou Petrochemical General Hospital
Lanzhou
Gang Yin
Lanzhou Second People's Hospital
Lanzhou
Xuehua Yan
The Second Hospital of Lanzhou University
Lanzhou
Rui Zhao
Dongfang Hospital of Lianyungang
Lianyungang
Shanmei Dai
Guanyun County Hospital of Traditional Chinese Medicine
Lianyungang
Minfei Wang
Guanyun County People's Hospital
Lianyungang
Qin Yang
Lianyungang Dongfang Hospital
Lianyungang
Shanmei Dai
Lianyungang First People's Hospital
Lianyungang
Tingting Zhang
Houma People's Hospital
Linfen
Shujun Gao
Linfen Central Hospital
Linfen
Yuefeng Chai
Linfen Second People's Hospital
Linfen
Hongxia Li
Linfen Third People's Hospital
Linfen
Fenxiang Li
Xiangfen County People's Hospital
Linfen
Wenyan Jing
Yaodu District People's Hospital
Linfen
Hui Zhang
Linkou County People's Hospital
Linkou
Li Sun
Hezheng County People's Hospital
Linxia
Guozhong Li
Linyi Hospital of Traditional Chinese Medicine
Linyi
Hezheng Shen
Linyi People's Hospital
Linyi
Feng Gao
Lishui Central Hospital
Lishui
Jie Yang
Liuzhou People's Hospital
Liuzhou
Shufang Yuan
Liuzhou Workers' Hospital
Liuzhou
Qian Guo
Longnan First People's Hospital
Longnan
Hong Zheng
Liancheng County Hospital
Longyan
Yanqin Wu
Longyan People's Hospital
Longyan
Jining Xu
Longyan Second Hospital
Longyan
Qingdong Tong
Tingzhou Hospital of Changting County
Longyan
Yunyan Wu
Wuping County Hospital
Longyan
Jiansheng Huang
Affiliated Hospital of West Anhui Health Vocational College
Lu'an
Zhenxiang Zhu
Huoqiu First People's Hospital
Lu'an
Qingming Duan
Huoqiu Second People's Hospital
Lu'an
Lin Dong
Huoshan County Hospital
Lu'an
Jun Zhan
Jinzhai County Hospital of Traditional Chinese Medicine
Lu'an
Wu Liu
Lu'an Fourth People's Hospital
Lu'an
Minglan Tao
Lu'an Hospital of Traditional Chinese Medicine
Lu'an
Wei He
Lu'an People's Hospital
Lu'an
Jianguo Rao
Lu'an Yeji District People's Hospital
Lu'an
Lianghuan Geng
Lvliang People's Hospital
Lüliang
Xiaoling Li
Wenshui County People's Hospital
Lüliang
Lizhen Hou
Ma'anshan Fourth People's Hospital
Ma’anshan
The Second Affiliated Hospital of Wannan Medical College
Ma’anshan
Wenjun Yao
Macheng People's Hospital
Macheng
Jingfeng Chen
Huazhou People's Hospital
Maoming
Bozhi Chen
Meishan People's Hospital
Meishan
Junying Liu
Mudanjiang Kang'an Hospital
Mudanjiang
Yanxia Zhang
Mudanjiang Second People's Hospital
Mudanjiang
Weiwei Pan
Jiangxi Provincial People's Hospital
Nanchang
Yuanmei Che
Nanchang County People's Hospital
Nanchang
Chengyun Yang
Nanchang Ninth Hospital
Nanchang
Zhicheng Zhang
The First Affiliated Hospital of Nanchang University
Nanchang
Xiaoping Wu
The Second Affiliated Hospital of Nanchang University
Nanchang
Shuilin Sun
Nanbu County People's Hospital
Nanchong
Tonggang Liu
Nangong People's Hospital
Nangong
Peng Gao
Jiangsu Provincial People's Hospital
Nanjing
Chuanlong zhu
Lishui District People's Hospital
Nanjing
Chunyan Fan
Nanjing Drum Tower Hospital
Nanjing
Jie Li
Nanjing Hospital of Traditional Chinese Medicine
Nanjing
Yanliang Zhang
Nanjing Second Hospital
Nanjing
Wei Ye
Nanjing Tianyinshan Hospital
Nanjing
Maorong Wang
Qinhuai Medical District of Eastern Theater General Hospital
Nanjing
Lecheng Yu
The Fourth Affiliated Hospital of Nanjing Medical University
Nanjing
Jie Yin
Zhongda Hospital
Nanjing
Qun Zhang
The First Affiliated Hospital of Guangxi Medical University
Nanning
Yanhong Yu
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning
Fuli Long
The Second Affiliated Hospital of Guangxi Medical University
Nanning
Keli Wei
The Second People's Hospital of Nanning
Nanning
Ziyu Liang
Jianyang First Hospital of Nanping
Nanping
Xiaoying Wang
Nanping First Hospital
Nanping
Yuanzhong Gong
Zhenghe County Hospital
Nanping
Affiliated Hospital of Nantong University
Nantong
Haimen District People's Hospital
Nantong
Aidong Xu
Nantong Third People's Hospital
Nantong
Xianjin Liu
Qidong Third People's Hospital
Nantong
Bairin Left Banner People's Hospital
Neimeng
Yanping Gao
Hulunbuir People's Hospital
Neimeng
Xin Lu
Morin Dawa Daur Autonomous Banner People's Hospital
Neimeng
About this study
Official title: A Real-World Study on Reducing the Risk of Liver Cancer in Chronic Hepatitis B Patients With a Family History of HBV-Related Liver Cancer.
This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. The primary endpoint is the incidence rate of HCC, and secondary endpoints include the rate of HBsAg seroclearance, changes in liver fibrosis, and survival rates. The study will last for 5 years and enroll approximately 15,000 patients, aiming to provide evidence-based optimization for CHB treatment regimens.
- Being tested
- ETV,TDF,TAF,TMF combination with PEG IFNα-2b, ETV,TDF,TAF or TMF
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ETV,TDF,TAF,TMF combination with PEG IFNα-2bDrug
The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
ETV,TDF,TAF or TMFDrug
The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
| Study group | Role | What they receive |
|---|---|---|
| PEG IFNα-2b Group | Not described Receives: Drug: ETV,TDF,TAF,TMF combination with PEG IFNα-2b | |
| Nucleos(t)ide Monotherapy Group | Not described Receives: Drug: ETV,TDF,TAF or TMF |
What is being measured
The primary outcome is the main question the study is designed to answer.
5-year incidence of hepatocellular carcinoma (HCC)
Measured: From the start of antiviral treatment to 5 years of follow-up.
Secondary outcomes (10)
HBsAg seroclearance rate
Measured: From the start of antiviral treatment to 5 years of follow-up.
HBeAg seroclearance rate
Measured: From the start of antiviral treatment to 5 years of follow-up.
HBV DNA level
Measured: From the start of antiviral treatment to 5 years of follow-up.
HBsAg level
Measured: From the start of antiviral treatment to 5 years of follow-up.
HBeAg level
Measured: From the start of antiviral treatment to 5 years of follow-up.
Proportion of patients with improved or progressed liver fibrosis
Measured: From the start of antiviral treatment to 5 years of follow-up.
Median time to cirrhosis
Measured: From the start of antiviral treatment to 5 years of follow-up.
Median time to decompensated cirrhosis
Measured: From the start of antiviral treatment to 5 years of follow-up.
Median time to HCC
Measured: From the start of antiviral treatment to 5 years of follow-up.
Overall survival (OS)
Measured: From the start of antiviral treatment to 5 years of follow-up.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study startJun 2025 (estimated)
- Primary completionJan 2032 (estimated)
- Study completionDec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HBVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Guiqiang Wang, Peking University First Hospital
- Investigators
- Guiqiang Wang, Ph.D, Principal investigator, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07007286
- Sponsor's protocol ID
- 2025086
- Status last verified
- May 2025
- First submitted
- 28 May 2025
- Last updated
- 5 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Real-World Study on Reducing the Risk of Liver Cancer in Chronic Hepatitis B Patients With a Family History of HBV-Related Liver Cancer.
- ClinicalTrials.gov ID
- NCT07007286
- Acronym / sponsor ID
- 2025086
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- Jun 2025 (estimated)
- Primary completion
- Jan 2032 (estimated)
- Study completion
- Dec 2032 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. The primary endpoint is the incidence rate of HCC, and secondary endpoints include the rate of HBsAg seroclearance, changes in liver fibrosis, and survival rates. The study will last for 5 years and enroll approximately 15,000 patients, aiming to provide evidence-based optimization for CHB treatment regimens.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PEG IFNα-2b Group | – | Drug: ETV,TDF,TAF,TMF combination with PEG IFNα-2b |
| Nucleos(t)ide Monotherapy Group | – | Drug: ETV,TDF,TAF or TMF |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who meet the inclusion criteria but do not meet the exclusion criteria were screened from multiple centers nationwide.
Key inclusion criteria (1 listed)
- (1) Chronic hepatitis B (CHB) patients with HBsAg positivity for over 6 months; (2) Family history of HBV-related hepatocellular carcinoma (HCC) (first- or second-degree relatives with HBV-related HCC); (3) Age ≥ 30 years, regardless of gender; (4) Based on real-world clinical practice, patients receiving nucleos(t)ide analogue (NA) therapy, such as Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide Fumarate (TAF), or Tenofovir Amibufenamide (TMF), or those receiving combination therapy with nucleos(t)ide analogues and PEG IFNα-2b; (5) Negative pregnancy test within 24 hours before the first dose (for women of childbearing potential); (6) Voluntary participation, with the ability to understand and sign the informed consent form.
Key exclusion criteria (1 listed)
- (1) Patients diagnosed with hepatocellular carcinoma (HCC) or malignancies in other organ systems prior to treatment; (2) Patients with contraindications to Peg IFN α-2b (refer to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition) for details); (3) Patients in the immune-tolerant phase of HBV infection; (4) Patients scheduled for or with a history of organ transplantation; (5) Patients with hypersensitivity to interferon or any contraindication listed in the drug's prescribing information; (6) Other conditions deemed unsuitable for enrollment by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ETV,TDF,TAF,TMF combination with PEG IFNα-2bThe study will not involve any additional interventions, nor will it interfere with any related clinical decision-making. | Drug | PEG IFNα-2b Group |
| ETV,TDF,TAF or TMFThe study will not involve any additional interventions, nor will it interfere with any related clinical decision-making. | Drug | Nucleos(t)ide Monotherapy Group |
Primary outcome
5-year incidence of hepatocellular carcinoma (HCC)
Time frame: From the start of antiviral treatment to 5 years of follow-up.
10 secondary outcomes
HBsAg seroclearance rate
Time frame: From the start of antiviral treatment to 5 years of follow-up.
HBeAg seroclearance rate
Time frame: From the start of antiviral treatment to 5 years of follow-up.
HBV DNA level
Time frame: From the start of antiviral treatment to 5 years of follow-up.
HBsAg level
Time frame: From the start of antiviral treatment to 5 years of follow-up.
HBeAg level
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Proportion of patients with improved or progressed liver fibrosis
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Median time to cirrhosis
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Median time to decompensated cirrhosis
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Median time to HCC
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Overall survival (OS)
Time frame: From the start of antiviral treatment to 5 years of follow-up.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
Related trials for HBV
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Chronic Hepatitis B Virus (HBV) Infection
RecruitingObservational study
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Chronic Liver Disease and Cirrhosis, Liver Cancer
Not yet recruitingPhase 1
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Chronic Hepatitis B Virus
Recruiting
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
Hepatitis B, Vaccination; Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Guiqiang Wang, Ph.D principal investigator
Peking University First Hospital
555 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HBV and HCC, run by Peking University First Hospital at 555 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 555 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guiqiang Wang (01066119025, bdyyec@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5-year incidence of hepatocellular carcinoma (HCC) (time frame: From the start of antiviral treatment to 5 years of follow-up.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.